Why the study?
Autonomic nervous system disorder is an important basis for HF, and recent studies suggest SGLT2i effects on autonomic nervous function may represent a new mechanism improving HF.
Do SGLT2 inhibitors improve autonomic nervous function in patients with heart failure?
Do SGLT2 inhibitors improve autonomic nervous function in patients with heart failure?
SGLT2 inhibitors may improve heart failure outcomes partly through beneficial effects on autonomic nervous function.
Answers are grounded in this paper and cite their sources.
SGLT2i may lower HF events via autonomic effects; leaves open confirmation in prospective trials.
Heart failure (HF) seriously affects human health, and the autonomic nervous system disorder is an important basis for the occurrence and development of heart failure. Sodium-glucose cotransporter 2 inhibitor (SGLT2i) was originally used to treat diabetes. Basic and clinical studies have reported that SGLT2i is effective in reducing the incidence of heart failure, hospitalization, and all-cause mortality in patients with or without diabetes mellitus. Because of its significant cardiovascular benefits, SGLT2i has been used as a guideline in the treatment of heart failure. The mechanisms by which SGLT2i improves heart failure include regulation of volume, cardio-renal mechanism, metabolic action, improvement of myocardial remodeling, reduction of inflammation and oxidative stress. Recent studies have found that SGLT2i is closely related to autonomic nervous function, and may be a new mechanism to improve heart failure. This article focuses on discussing the benefits of SGLT2i on heart failure and its effects on autonomic nervous system, providing a new basis for clinical treatment of heart failure.
No takes yet. Share an insight, caveat, or question.
Li et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: